Skip links

Tag: oncology medication

ASCO Webinar Summary: Breast Cancer

KEYNOTE-355: A Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy vs. placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer ( Author, Company: Javier Cortes, MD, PhD Abstract Number: 1000 Indications: Triple Negative Breast Cancer Interventions: Pembrolizumab plus chemotherapy Background and objectives:

Call Now Button 
Contact Us